CD13作为前列腺特异性膜抗原阴性前列腺癌的潜在诊疗靶点及[18F]AlF-CD13-L1 PET/CT显像的首次人体研究
本研究通过定量蛋白分析在8例PSMA阴性前列腺癌和11例对照中鉴定CD13为PSMA阴性前列腺癌中上调最显著的膜蛋白,并在扩大队列中用免疫组化验证其阳性率。16例受试者接受[18F]AlF-CD13-L1 PET/CT显像,肿瘤SUVmax和瘤/肌肉比与CD13免疫组化评分呈正相关,CD13阳性肿瘤显示明显放射性摄取。
要点
- CD13是PSMA阴性前列腺癌的潜在靶点,在PSMA阴性前列腺癌中阳性率为92.9%(13/14)。
- CD13在PSMA阳性前列腺癌、导管腺癌和导管内癌中阳性率分别为82.7%(105/127)、91.7%(11/12)和70%(14/20)。
- [18F]AlF-CD13-L1在CD13阳性前列腺癌中选择性聚集,使肿瘤得以显像。
核心结论
- CD13是PSMA阴性前列腺癌的潜在靶点,且在PSMA阳性前列腺癌、导管腺癌和导管内癌中也显示高阳性率。
- [18F]AlF-CD13-L1在CD13阳性前列腺癌中选择性聚集,使肿瘤得以显像。
研究设计与样本
- 对8例PSMA阴性前列腺癌和11例对照进行定量蛋白分析以鉴定潜在分子靶点,并用免疫组化在扩大队列中验证。
- 16例受试者接受[18F]AlF-CD13-L1 PET/CT扫描,以前列腺癌病理组织为参考解读显像结果。
- 试验注册号ChiCTR2300077817,注册日期2023年11月21日。
主要发现
- 定量蛋白分析显示CD13是PSMA阴性前列腺癌中上调最显著的膜蛋白。
- CD13阳性率在PSMA阴性前列腺癌为92.9%(13/14),PSMA阳性前列腺癌为82.7%(105/127),导管腺癌为91.7%(11/12),导管内癌为70%(14/20)。
- 前列腺癌参与者中,肿瘤[18F]AlF-CD13-L1 PET/CT的SUVmax中位数为4.3(1.5-5.8),瘤/肌肉比中位数为4.6(1.7-6.1)。
- 前列腺癌病灶SUVmax与CD13免疫组化评分呈正相关(rspearman=0.6249,p=0.025),瘤/肌肉比与CD13免疫组化评分呈正相关(rspearman=0.6714,p=0.015)。
- CD13阳性肿瘤显示明显的放射性示踪剂聚集。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Approximately 10% of prostate cancer (PCa) are prostate-specific membrane antigen (PSMA)-negative, leading to blind spots in PSMA-based diagnosis. This study aimed to identify a potential target for PSMA-negative PCa and preliminarily evaluate the feasibility of using radionuclide probe targeting the identified target for PCa diagnosis. METHODS: Quantitative protein analysis was performed on eight PSMA-negative PCa and eleven controls to identify a potential molecular target, followed by validation with an expanded cohort using immunohistochemistry. Sixteen participants underwent [18F]AlF-CD13-L1 PET/CT scanning, with the PCa pathological tissues used as references to interpret the imaging results. RESULTS: Quantitative protein analysis revealed CD13 as the most significantly upregulated membrane protein in PSMA-negative PCa. Expanded validation results indicated that CD13 positivity rates were 92.9% (13/14), 82.7% (105/127), 91.7% (11/12), and 70% (14/20) in PSMA-negative PCa, PSMA-positive PCa, ductal adenocarcinoma of the prostate (DAC), and intraductal carcinoma of the prostate (IDC-P), respectively. In PCa participants, the median [18F]AlF-CD13-L1 PET/CT maximum standardized uptake value (SUVmax) of tumors and tumor-to-muscle ratio were 4.3 (1.5-5.8) and 4.6 (1.7-6.1), respectively. The SUVmax value of the PCa lesions and the tumor-to-muscle ratio showed a positive correlation with the immunohistochemical score of CD13 of the PCa lesions (rspearman = 0.6249, p = 0.025; rspearman = 0.6714, p = 0.015, respectively), with CD13-positive tumors showing significant radiotracer accumulation. CONCLUSION: CD13 was a potential target for PSMA-negative PCa and also showed high positivity rates in PSMA-positive PCa, DAC, and IDC-P. [18F]AlF-CD13-L1 selectively accumulated in CD13-positive PCa, enabling visualization. (Trial registration: ChiCTR2300077817. Registered November 21, 2023).
引用
- Tang W, Zhou M, Lu C, et al. CD13 as a potential theranostic target for prostate-specific membrane antigen-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging. Eur J Nucl Med Mol Imaging. 2025. PMID: 39985618. doi:10.1007/s00259-025-07140-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。